145 related articles for article (PubMed ID: 20683345)
1. Cardiac involvement in patients with hematologic malignancies.
Allegra A; Alonci A; Russo S; Cannavò A; Penna G; D'Angelo A; Bellomo G; Musolino C
J Investig Med; 2010 Oct; 58(7):859-74. PubMed ID: 20683345
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity induced by tyrosine kinase inhibitors.
Orphanos GS; Ioannidis GN; Ardavanis AG
Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline-induced cardiotoxicity in adult hematologic malignancies.
Johnson SA
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S22-7. PubMed ID: 16781286
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
5. Cardiac toxicity from systemic cancer therapy: a comprehensive review.
Curigliano G; Mayer EL; Burstein HJ; Winer EP; Goldhirsch A
Prog Cardiovasc Dis; 2010; 53(2):94-104. PubMed ID: 20728696
[TBL] [Abstract][Full Text] [Related]
6. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
Straus DJ; Testa MA; Sarokhan BJ; Czuczman MS; Tulpule A; Turner RR; Riggs SA
Cancer; 2006 Oct; 107(8):1909-17. PubMed ID: 16977654
[TBL] [Abstract][Full Text] [Related]
7. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
8. [Cardiotoxicity of antracycline treatment in the light of new biochemical diagnostic options].
Urbanová D; Mladosievicová B
Vnitr Lek; 2007 Jun; 53(6):669-77. PubMed ID: 17702127
[TBL] [Abstract][Full Text] [Related]
9. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
11. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997.
Murdych T; Weisdorf DJ
Bone Marrow Transplant; 2001 Aug; 28(3):283-7. PubMed ID: 11535997
[TBL] [Abstract][Full Text] [Related]
12. [Modern therapy of hematologic malignancies].
Trnĕný M
Cas Lek Cesk; 2001 Nov; 140(23):711-6. PubMed ID: 11787232
[TBL] [Abstract][Full Text] [Related]
13. Intravascular clotting activation and bleeding in patients with hematologic malignancies.
Tallman MS; Kwaan HC
Rev Clin Exp Hematol; 2004 Jun; 8(1):E1. PubMed ID: 16029967
[TBL] [Abstract][Full Text] [Related]
14. Hematologic malignancies in patients with cryoglobulinemia: association with autoimmune and chronic viral diseases.
Trejo O; Ramos-Casals M; López-Guillermo A; García-Carrasco M; Yagüe J; Cervera R; Font J; Ingelmo M
Semin Arthritis Rheum; 2003 Aug; 33(1):19-28. PubMed ID: 12920693
[TBL] [Abstract][Full Text] [Related]
15. [Late infectious complications after high-dose therapy and autologous blood stem cell transplantation].
Metzner B; Grüneisl R; Gebauer W; Reschke D; Ost E; Müller TH; Reichert D; Rosien B; Del Valle F; Zirpel I; Kohse KP; Schunter F; Illiger HJ
Med Klin (Munich); 2002 Nov; 97(11):650-8. PubMed ID: 12434273
[TBL] [Abstract][Full Text] [Related]
16. Cardiac side-effects of cancer chemotherapy.
Monsuez JJ; Charniot JC; Vignat N; Artigou JY
Int J Cardiol; 2010 Sep; 144(1):3-15. PubMed ID: 20399520
[TBL] [Abstract][Full Text] [Related]
17. Cardiac troponin I in patients with hematologic malignancies.
Missov E; Calzolari C; Davy JM; Leclercq F; Rossi M; Pau B
Coron Artery Dis; 1997; 8(8-9):537-41. PubMed ID: 9431482
[TBL] [Abstract][Full Text] [Related]
18. High susceptibility to severe infectious complications at reinduction chemotherapy in patients who relapse after stem cell transplantation.
Iguchi A; Kobayashi R; Sato TZ; Naito H; Shikano T; Ishikawa Y; Kobayashi K
Transplant Proc; 2010 Jun; 42(5):1857-61. PubMed ID: 20620537
[TBL] [Abstract][Full Text] [Related]
19. Advancing the treatment of hematologic malignancies through the development of targeted interventions.
Tallman MS
Semin Hematol; 2002 Oct; 39(4 Suppl 3):1-5. PubMed ID: 12447845
[TBL] [Abstract][Full Text] [Related]
20. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
